{"id":"W2950604500","doi":"10.1097/01.hs9.0000562556.40615.f8","title":"PS1065 OPEN‐LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3‐MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Cohort; Chemotherapy; Surgery; Internal medicine; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002282433,0.002228869,0.00317762,0.0006064186,0.0005272042,0.001228856,0.0009743627,0.001572161,0.006067828],"category_scores_gemma":[0.001339004,0.0007183128,0.002653505,0.0004909683,0.001651712,0.001516409,0.0005702304,0.004209987,0.001422944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001296094,"about_ca_system_score_gemma":0.002130976,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001060409,"about_ca_topic_score_gemma":0.002323424,"domain_scores_codex":[0.9991806,0.0003737654,0.00004768762,0.0001811098,0.00008198124,0.0001349085],"domain_scores_gemma":[0.998494,0.0002283958,0.0002922693,0.0001376927,0.00009512142,0.0007525273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9371862,0.02771243,0.00511622,0.0002382233,0.00129695,0.0001429202,0.0001065541,0.0008226244,0.007078584,0.0001056611,0.001657491,0.01853626],"study_design_scores_gemma":[0.6404585,0.3388728,0.01605798,0.00002032739,0.0008255874,0.0001517583,0.00005000392,0.0007399851,0.001218966,0.0001581416,0.001411945,0.00003406116],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933216,0.0008672475,0.000323322,0.0002902292,0.000134738,0.001330853,0.002292901,0.00007583459,0.001363337],"genre_scores_gemma":[0.9873819,0.0009489953,0.0008664594,0.0008666718,0.0004172944,0.001699919,0.00535313,0.00002437638,0.002441369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006067828,"threshold_uncertainty_score":0.02029896,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04942912092761675,"score_gpt":0.3420307488687258,"score_spread":0.292601627941109,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}